Trials / Conditions / Non-Hodgkin Lymphoma (NHL)

Non-Hodgkin Lymphoma (NHL)

23 registered clinical trials studyying Non-Hodgkin Lymphoma (NHL) — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas NCT07478848	Abramson Cancer Center at Penn Medicine	Phase 1
Not Yet Recruiting	Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia. NCT07518329	Arovella Therapeutics Ltd	Phase 1
Recruiting	NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma NCT07114367	NOBO Medicine	Phase 1
Recruiting	Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymph NCT07312630	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	EARLY_Phase 1
Recruiting	An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection NCT07101705	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	EARLY_Phase 1
Not Yet Recruiting	High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ) NCT06646211	Sun Yat-sen University	Phase 2
Completed	Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphoc NCT05225584	Kymera Therapeutics, Inc.	Phase 1
Terminated	VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractor NCT04702425	Novartis Pharmaceuticals	Phase 1
Recruiting	CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies NCT04186520	Medical College of Wisconsin	Phase 1 / Phase 2
Completed	Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels NCT04537715	Epizyme, Inc.	Phase 1
Suspended	Safety and Efficacy Evaluation of CD19-UCART NCT03229876	Bioray Laboratories	N/A
Active Not Recruiting	TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in NCT03849651	St. Jude Children's Research Hospital	Phase 2
Unknown	Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study NCT03260101	Cellect Biotechnology	—
Completed	A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated NCT02875548	Epizyme, Inc.	Phase 1 / Phase 2
Active Not Recruiting	Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haplo NCT02790515	St. Jude Children's Research Hospital	Phase 2
Terminated	Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation NCT02259348	St. Jude Children's Research Hospital	Phase 2
Completed	Study Evaluating Venetoclax in Subjects With Hematological Malignancies NCT02265731	AbbVie	Phase 1 / Phase 2
Active Not Recruiting	Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Im NCT01829958	Memorial Sloan Kettering Cancer Center	N/A
Completed	Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab NCT01707628	St. Antonius Hospital	N/A
Completed	Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level NCT01396070	Youn Kim	Phase 2
Terminated	Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells NCT01050764	Everett Meyer	Phase 1 / Phase 2
Terminated	Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT NCT01220297	Stanford University	Phase 2
Recruiting	Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL) NCT03199066	Czech Lymphoma Study Group	—